Tiziana Life Sciences Ltd
TLSA
$1.18
$0.054.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.73% | 23.56% | 49.78% | 26.68% | 7.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.80% | 25.36% | 16.93% | 1.43% | -12.18% |
| Operating Income | -33.80% | -25.36% | -16.93% | -1.43% | 12.18% |
| Income Before Tax | -10.06% | 1.57% | 13.29% | 7.99% | 2.88% |
| Income Tax Expenses | -- | 79.94% | 45.88% | -165.24% | -1,187.53% |
| Earnings from Continuing Operations | -55.37% | -22.20% | 6.46% | 21.37% | 32.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.37% | -22.20% | 6.46% | 21.37% | 32.94% |
| EBIT | -33.80% | -25.36% | -16.93% | -1.43% | 12.18% |
| EBITDA | -33.82% | -25.38% | -16.95% | -1.42% | 12.21% |
| EPS Basic | -40.14% | -9.99% | 14.97% | 26.78% | 35.92% |
| Normalized Basic EPS | -27.46% | -17.41% | -7.47% | 4.60% | 14.98% |
| EPS Diluted | -40.14% | -9.99% | 14.97% | 26.78% | 35.92% |
| Normalized Diluted EPS | -27.46% | -17.41% | -7.47% | 4.60% | 14.98% |
| Average Basic Shares Outstanding | 10.88% | 10.62% | 10.35% | 7.23% | 4.10% |
| Average Diluted Shares Outstanding | 10.88% | 10.62% | 10.35% | 7.23% | 4.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |